Search the site
Meghan A. Dureen, Ph.D.
Counsel
Meghan Dureen practices exclusively in the area of intellectual property law with a focus on proceedings under the Patented Medicines (Notice of Compliance) Regulations. Dr. Dureen completed her J.D. at the University of Toronto. Prior to law school, Dr. Dureen received a Bachelor of Science in Chemistry from the University of British Columbia and a Ph.D. in Chemistry from the University of Toronto. Her research has been published in scientific journals including the Journal of the American Chemical Society, Inorganic Chemistry and Organometallics.
Education
- B.Sc., University of British Columbia
- Ph.D., University of Toronto
- J.D., University of Toronto
Bar Admission
- Ontario, 2014
My recent cases
Proceeding for patent impeachment relating to pembrolizumab.
Application for a declaration of non‑infringement regarding pembrolizumab.
Application for a declaration of non‑infringement regarding pembrolizumab.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding apalutamide.
Action under section 8.2 of the Patented Medicines (Notice of Compliance) Regulations regarding apalutamide.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding apalutamide.
Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding aflibercept.
Action under section 8.2 of the Patented Medicines (Notice of Compliance) Regulations regarding aflibercept.
Action under section 8.2 of the Patented Medicines (Notice of Compliance) Regulations regarding aflibercept.
Action under section 8.2 of the Patented Medicines (Notice of Compliance) Regulations regarding aflibercept.
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,832,157 (brexpiprazole).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,602,247 (brexpiprazole).
Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,851,588 (brexpiprazole).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,752,437 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,696,558 and 2,752,435 (empagliflozin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,649,922 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,732,803 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,782,179 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,696,558 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,738,367 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,557,801, 2,606,650, 2,751,833 and 2,813,661 (empagliflozin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,496,249 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,589,765, 2,589,921, 2,701,778, 2,741,312 and 2,873,044 (carfilzomib).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,731,370 and 2,764,475 (selexipag).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,731,370 and 2,764,475 (selexipag).
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent Nos. 2,621,273 and 2,659,770 (macitentan).
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,794,060 (pomalidomide).
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,752,550 (pomalidomide).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,819,967 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,710,358 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,710,014 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,631,646 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,937,365 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,667,654 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,620,380 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,709,997 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,762,013 and 2,620,380 (pirfenidone).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,540,547, 2,596,133, 2,376,596 and 2,407,556 (trastuzumab).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,540,547, 2,596,133, 2,376,596 and 2,407,556 (trastuzumab).
Motion/Application under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,540,547, 2,596,133, 2,376,596 and 2,407,556 (trastuzumab).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,507,002 and 2,496,780 (silodosin).
Patent impeachment case regarding Patent No. 2,596,133 (trastuzumab).
Patent infringement case regarding Patent No. 2,787,952 (bevacizumab) with counterclaim for infringement under the new Patented Medicines (Notice of Compliance) Regulations.
Patent impeachment case regarding Patent No. 2,376,596 (trastuzumab).
Patent impeachment case regarding Patent No. 2,540,547 (trastuzumab).
Patent infringement case regarding Patent No. 2,407,556 (trastuzumab).
Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,705,733 (acetaminophen).
Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,415,403 (acetaminophen).
Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,366,785 and 2,476,934 (etanercept).
More people
.jpg)
.jpg)
.jpg)
.jpeg)
.jpg)
%20(1).jpg)
.jpg)
.jpg)
